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Background: Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based
chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET domain
(MMSET) and ubiquitin-conjugating enzyme 9 (UBC9) are involved in DNA repair and could modify the BRCA1 predictive model.
Methods: Mediator of DNA damage checkpoint protein 1, 53BP1, MMSET and UBC9 mRNA were assessed in gastric tumours
from patients in whom BRCA1 levels had previously been determined.
Results: In vitro chemosensitivity assay, MMSET levels were higher in docetaxel-sensitive samples. In a separate cohort, survival
was longer in those with low MMSET (12.3 vs 8.8 months; P¼ 0.04) or UBC9 (12.4 vs 8.8 months; P¼ 0.01) in patients receiving only
folinic acid, fluorouracil (5-FU) and oxaliplatin (FOLFOX). Conversely, among patients receiving second-line docetaxel, longer
survival was associated with high MMSET (19.1 vs 13.9 months; P¼ 0.003). Patients with high MMSET and BRCA1 attained a
median survival of 36.6 months, compared with 13.9 months for those with high BRCA1 and low MMSET (P¼ 0.003). In the
multivariate analyses, low MMSET (hazard ratio (HR), 0.59; P¼ 0.04) and low UBC9 (HR, 0.52; P¼ 0.01) levels were markers of longer
survival to first-line FOLFOX, whereas palliative surgery (HR, 2.47; P¼ 0.005), low BRCA1 (HR, 3.17; P¼ 0.001) and low MMSET (HR,
2.52; P¼ 0.004) levels were markers of shorter survival to second-line docetaxel.
Conclusions: Breast cancer susceptibility gene 1, MMSET and UBC9 can be useful for customising chemotherapy in gastric cancer
patients.
Gastric cancer represents 8% of total cancer cases and 10%
of total deaths worldwide, with an annual estimate of 989 600
new cases and 738 000 deaths (Jemal et al, 2011). China accounts
for 40% of all gastric cancer patients, most of whom are
diagnosed with advanced disease (Jemal et al, 2011). The outcome
for locally advanced and metastatic gastric cancer is still
dismal, with a median survival of o1 year (Wagner et al, 2006).
In our previous experience, however, median survival was
15.8 months in gastric cancer patients with low mRNA
expression of excision repair cross-complementing 1 (ERCC1)
treated with the combination of folinic acid, fluorouracil
(5-FU) and oxaliplatin (FOLFOX) (Wei et al, 2008). We also
found that among patients receiving second-line docetaxel,
median overall survival was 25.8 months for patients with high
mRNA expression of breast cancer susceptibility gene 1 (BRCA1;
Wei et al, 2011).
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Chemotherapy induces widespread DNA damage. Although
ERCC1 and BRCA1 can affect survival to chemotherapy because of
their pivotal roles in DNA damage response pathways, recent
studies have revealed a more complex network involved in the
response to DNA damage. Preclinical evidence showed that
receptor-associated protein 80 (RAP80) is essential for the BRCA1
repair function (Sobhian et al, 2007; Morris et al, 2009). In
addition, BRCA1 is also modified by small ubiquitin-related
modifier (SUMO) in response to genotoxic damage. Protein
inhibitor of activated STAT (PIAS) SUMO ligases are required for
proficient double-strand break repair (Galanty et al, 2009), which
has been investigated in our previous study (Wei et al, 2011). In
DNA damage repair, mediator of DNA damage checkpoint protein
1 (MDC1) serves as a upstream molecular, which promotes H2AX
phosphorylation and then helps to amplify ataxia telangiectasia
mutated signalling by a time-dependent, sequential assembly of
repair proteins, including BRCA1 and p53-binding protein 1
(53BP1), thus controlling damage-induced cell cycle arrest
checkpoints (Stewart et al, 2003; Stucki et al, 2005). The function
of 53BP1 in DNA repair is abrogated when BRCA1 is depleted
(Rauch et al, 2005; Bunting et al, 2010). Impaired 53BP1
accumulation to DNA damage sites was also observed along with
depletion of PIAS4 and ubiquitin-conjugating enzyme 9 (UBC9),
the E3 and E2 ubiquitin ligases in the SUMO conjugation system
(Galanty et al, 2009). Ubiquitin-conjugating enzyme 9 transports
BRCA1 proteins to the nucleus, and knockdown of UBC9 resulted
in cytoplasmic localisation of BRCA1 proteins, which were
impaired in their capacity to inhibit growth of ovarian cancer
cells (Qin et al, 2012). The methyltransferase multiple myeloma
SET domain (MMSET) has a central role in the recruitment of
53BP1 to DNA damage sites (Pei et al, 2011), and depletion of
MMSET confers hypersensitivity to ionising radiation (Pei et al,
2011). Multiple myeloma SET domain is highly expressed in
several tumour types compared with normal tissues (Kassambara
et al, 2009; Hudlebusch et al, 2011a), and high MMSET expression
contributes to cell viability and growth and thus to poor prognosis
(Hudlebusch et al, 2011b). In addition, MMSET knockdown
decreased transcript levels of several cell cycle genes, including
BRCA1 (Brito et al, 2009; Figure 1).
In order to examine the impact of MDC1, 53BP1, MMSET
and UBC9 on the predictive model based on BRCA1 mRNA
expression, we have analysed the mRNA expression of these
genes in tumour samples from two separate cohorts of advanced
gastric cancer patients. In 99 patients, we correlated expression
levels with in vitro cytotoxicity of cisplatin and docetaxel,
and in the second cohort of 132 advanced gastric cancer patients
in whom BRCA1 mRNA expression had previously been
determined (Wei et al, 2011), we correlated expression levels with
survival to first-line FOLFOX and to second-line docetaxel-based
chemotherapy.
MATERIALS AND METHODS
Patients. Freshly removed gastric tumour tissues were obtained
from 99 patients undergoing gastrectomy between 2010 and 2011
at the General Surgery Department of Drum Tower Hospital,
Nanjing, China. Gene expression levels of MDC1, 53BP1, MMSET
and UBC9 were determined and correlated with in vitro tumour
chemosensitivity. In a second independent cohort of 132 patients
(Wei et al, 2011) with histologically proven locally advanced or
metastatic gastric cancer and Eastern Cooperative Oncology Group
(ECOG) performance status (PS) p2, we examined the expression
of the four genes in tumour samples obtained at the time of
surgical resection and correlated gene expression levels with overall
survival. All patients received a modified FOLFOX regimen as first-
line chemotherapy, and 58 patients were also treated with second-
line docetaxel-based chemotherapy. Thirty-five patients received
single-agent docetaxel and the remaining 23 patients were treated
with docetaxel-based doublets, based on their response to first-line
chemotherapy, PS and patient consent.
Survival was calculated from the starting date of first-line
treatment to the date of last follow-up or death from any cause. All
patients gave their signed informed consent, and the study was
approved by the institutional ethics review board of Drum Tower
Hospital.
In vitro chemosensitivity. Sensitivity to docetaxel and cisplatin
was examined in vitro by histoculture drug response assay
(Furukawa et al, 1995). Briefly, fresh tumour specimens were cut
into small pieces of approximately 10 mg and then placed on
prepared collagen surfaces in 24-well microplates. After treatment
with docetaxel and cisplatin at the concentration of 100 mg ml–1
(Hayashi et al, 2009) and 20 mg ml–1 (Fujita et al, 2009), respectively,
3-(4,5-dimethyl-2-thiazotyl)-2,5-diphenyl-2H-tetrazoliumbromide assay
was used to examine cytotoxicity. The inhibition rate was
calculated as previously reported (Shen et al, 2012).
Gene expression analysis. Breast cancer susceptibility gene 1
expression had previously been determined in all patients (Wei
et al, 2011). We analysed the mRNA expression of MDC1, 53BP1,
MMSET and UBC9 by quantitative PCR. RNA was isolated from
the macrodissected tumour tissue specimens in accordance with a
proprietary procedure (European patent number EP1945764-B1).
Briefly, paraffin was removed by xylene. Macrodissected tumour
samples were lysed in a proteinase K-containing buffer. RNA was
then purified with phenol–chloroform–isoamyl alcohol, followed
by precipitation with isopropanol in the presence of glycogen and
sodium acetate. RNA was re-suspended in water and treated with
DNAse I to avoid DNA contamination. cDNA was generated using
M-MLV retrotranscriptase enzyme. Template cDNA was amplified
with specific primers and probes for each gene and Taqman
Universal Master Mix (Applied Biosystems, Foster City, CA, USA).
Quantification of gene expression was performed using the ABI
Prism 7900HT Sequence Detection System (Applied Biosystems).




















Figure 1. The MDC–MMSET–UBC9–53BP1–BRCA1 pathway. In
response to DNA double-stand breaks, MDC1 directly binds to histone
H2A variant H2AX, regulating cellular responses to DNA repair by
BRCA1 and 53BP1. Breast cancer susceptibility gene 1 needs to be
SUMOylated through the activity of UBC9-PIAS1/4 at sites of DNA
damage to increase its ubiquitin ligase activity. Multiple myeloma SET
domain is required for the recruitment of 53BP1 to DNA damage sites.
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Ct values o0.30 were accepted. Relative gene expression quanti-
fications were calculated according to the comparative Ct method
using b-actin as an endogenous control and commercial human
lung and liver RNA (Stratagene, La Jolla, CA, USA) as calibrators.
Final results were determined by the formula 2DDCt and were
performed according to Technical Bulletin #2 (Applied Biosystems).
Statistical analysis. Median values and ranges were calculated for
quantitative variables and gene mRNA expression. Qualitative
variables were summarised by absolute frequencies and percen-
tages. The normality of quantitative variables was analysed by the
Kolmogorov–Smirnov test and compared with the Mann–Whitney
U and Kruskal–Wallis tests. In order to correlate gene expression
levels with clinical characteristics, the w2 test or Fisher’s exact test
was used for qualitative variables. The Spearman rho method was
used to correlate the expression levels of the four genes. The Mann-
Whitney U-test was used to compare gene expression levels in
chemosensitive and chemoresistant groups. The distributions of
survival were obtained by the Kaplan–Meier method and
compared with the log-rank test. A univariate analysis was
performed to evaluate the survival differences according to gender,
ECOG PS, histology, site, stage or expression levels of MDC1,
53BP1, MMSET and UBC9. A multivariate analysis was performed
and the hazard ratio (HR) and 95% confidence intervals (CIs) were
estimated with the use of the forward and backward Cox
proportional hazards model.
All statistical calculations were performed with the Statistical
Package for the Social Sciences for Windows version 17 (SPSS Inc.,
Chicago, IL, USA) and S-Plus 6.1 (Insightful Corporation, Seattle,
WA, USA). Two-sided P-values o0.05 was considered statistically
significant.
RESULTS
Patient characteristics. The in vitro study included 99 gastric
cancer patients. All patients had adenocarcinoma, and 73.3% were
males. The clinical study included a separate cohort of 132 gastric
cancer patients in whom BRCA1 expression had previously been
analysed (Wei et al, 2011). Median age was 60.5 years (range,
22–84); 102 patients were males; 90.9% had PS 0–1; 98.4% had
adenocarcinoma. Curative gastrectomy was performed in 65.9% of
the patients, while the rest received palliative surgery. Forty
patients (30.3%) had stage IIIA, 41 (31.1%) stage IIIB and 51
(38.6%) stage IV disease at the time of diagnosis (Table 1). The
median number of cycles of FOLFOX was three (range, 1–8). All
patients progressed to first-line chemotherapy, and 58 patients
were treated with second-line docetaxel chemotherapy. The
median number of cycles of second-line chemotherapy was three
(range, 1–7). The median age of patients receiving second-line
docetaxel-based therapy was younger than those treated only with
first-line chemotherapy (58 vs 64 years, P¼ 0.05). No other
differences were observed between patients receiving and those not
receiving second-line therapy (Table 1).
Gene expression levels and in vitro chemosensitivity. The
expression levels of MDC1, 53BP1 and MMSET were successfully
assessed in 94 of the 99 samples, whereas UBC9 expression was
assessed in 90 samples. In the in vitro study, the median gene
expression relative to the housekeeping b-actin gene was 1.1 for
MDC1 (range, 0.05–18.8), 3.6 for 53BP1 (range, 0.2–23.4), 3.3 for
MMSET (range, 0.1–35.8) and 2.5 for UBC9 (range, 0.04–13.1).
When the gastric cancer samples were divided into chemosensitive
and chemoresistant subgroups by the median value of inhibition to












Median (range) 60.5 (22–84) 64 (22–84) 58 (29–81) 0.05
Gender
Female 31 (23.5) 20 (27) 11 (19) 0.30
Male 101 (76.5) 54 (73) 47 (81)
ECOG PS
o2 120 (90.9) 65 (87.8) 55 (94.8) 0.22
2 12 (9.1) 9 (12.2) 3 (5.2)
Histology
Adenocarcinoma 130 (98.4) 73 (98.6) 57 (98.3) 0.30
Adenosquamous 1 (0.8) 0 (0) 1 (1.7)
Squamous cell carcinoma 1 (0.8) 1 (1.4) 0 (0)
Stage
IIIA 40 (30.3) 25 (33.8) 15 (25.9) 0.35
IIIB 41 (31.1) 19 (25.7) 22 (37.9)
IV 51 (38.6) 30 (40.5) 21 (36.2)
Surgery
Curative 87 (65.9) 46 (62.2) 41 (70.7) 0.17
Palliative 45 (34.1) 28 (37.8) 17 (29.3)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; FOLFOX¼ folinic acid þ fluorouracil þ oxaliplatin; PS¼performance status.
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docetaxel or cisplatin, MMSET mRNA levels were higher in the
docetaxel-sensitive than in the docetaxel-resistant group (7.17 vs 3.63;
P¼ 0.013; Figure 2). No other differences in gene expression
were observed between the chemosensitive and chemoresistant
groups.
Gene expression levels and overall survival. BRCA1 expression
levels had previously been determined in all 132 patients (Wei et al,
2011). The expression levels of MDC1, 53BP1, MMSET and UBC9
were successfully assessed in all samples. The median gene
expression relative to the housekeeping b-actin gene was 3.3 for
MDC1 (range, 0.5–43.7), 5.7 for 53BP1 (range, 1.2–66), 6.5 for
MMSET (range, 0.8–73.6) and 1.9 for UBC9 (range, 0.3–13.2).
Patients were classified as having high or low gene expression using
the median as cutoff. No differences in clinical characteristics were
observed according to the mRNA expression levels of any of the
four genes.
With a median follow-up of 13.7 months (range, 1.3–68.1
months), median survival was 11.6 months (95% CI, 9.8–13.4
months) for all 132 patients. There was no difference in overall
survival time according to the expression levels of any of the genes.
Median survival time for the 58 patients receiving second-line
therapy was 14.9 months (95% CI, 11.6–18.3 months), compared
with 9.9 months (95% CI, 8.2–11.7 months) for those receiving
only first-line chemotherapy (P¼ 0.03).
Among patients receiving only first-line therapy, median
survival was 12.3 months (95% CI, 7.9–16.6 months) for those
with low levels of MMSET, compared with 8.8 months (95% CI,
5.9–11.7 months) for those with high levels (P¼ 0.04; Figure 3A).
Median survival was 12.4 months (95% CI, 10.2–14.5 months) for
those with low levels of UBC9 and 8.8 months (95% CI, 5.8–11.8
months) for those with high levels (P¼ 0.01; Figure 3B). Longer
survival was also observed in patients with low levels of MDC1
(P¼ 0.49) and 53BP1 (P¼ 0.09), although the difference was not
significant. As previously reported in this patient cohort, longer
trend of survival was also observed in patients with low BRCA1
expression (P¼ 0.20; Wei et al, 2011). Among patients with low
MMSET expression, median survival was 19.9 months (95% CI,
0.7–39.1 months) for those with low 53BP1 levels and 5.9 months
(95% CI, 1.6–10.3 months) for those with high 53BP1 levels
(P¼ 0.02; Figure 4). A nonsignificant trend towards longer survival
was observed in those with low UBC9 levels (P¼ 0.36), those with
low BRCA1 levels (P¼ 0.36) and those with low MDC1 levels
(P¼ 0.67).
1.0
Low MMSET (n=36 patients)
High MMSET (n=32 patients)
Median OS, 12.3 months (95% CI = 7.9–16.6 months)
Median OS, 8.8 months (95% CI = 5.9–11.7 months)
P=0.04
Low UBC9 (n=34 patients)
High UBC9 (n=36 patients)
Median OS, 12.4 months (95% CI = 10.2–14.5 months)
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Figure 3. Kaplan–Meier estimates of overall survival in advanced gastric cancer patients receiving only first-line FOLFOX chemotherapy
according to (A) MMSET and (B) UBC9 mRNA expression levels.
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Low MMSET and low 53BP1 (n=23 patients)
Low MMSET and high 53BP1 (n=6 patients)
Median OS, 19.9 months (95% CI = 0.7–39.1 months
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Figure 4. Kaplan–Meier estimates of overall survival in advanced
gastric cancer patients receiving only first-line FOLFOX chemotherapy






















Figure 2. Multiple myeloma SET domain mRNA levels in docetaxel-
sensitive and docetaxel-resistant gastric cancer samples.
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Among the 58 patients receiving second-line chemo-
therapy, those with high MMSET levels had longer survival (19.1
months; 95% CI, 5.2–33.1 months) than those with low levels (13.9
months; 95% CI, 7.1–20.7 months; P¼ 0.003; Figure 5A).
As previously reported, longer survival was also attained by
patients with high levels of BRCA1 (28.6 months; 95% CI, 20.2–
36.9 months) compared with those with low levels (9.8 months;
95% CI, 7.2–12.5 months; Po0.0001; Wei et al, 2011).
A nonsignificant trend toward longer survival was also observed
in patients with high expression of MDC1 (P¼ 0.07),
53BP1 (P¼ 0.36) and UBC9 (P¼ 0.17). In the subgroup of 25
patients with high BRCA1 levels receiving second-line chemo-
therapy, overall survival was 36.6 months (95% CI, 23.6–49.6
months) in patients with high MMSET levels and 13.9 months
(95% CI, 3.2–24.6 months) in those with low levels (P¼ 0.003;
Figure 5B). Two-year survival was 70.6% (95% CI, 48.8–92.3%) in
patients with high BRCA1 and high MMSET levels, compared with
25% (95% CI, 0.1–54.9%) in those with high BRCA1 but low
MMSET levels. Five-year survival rates were 33% (95% CI,
7.7–58.3%) for patients with high BRCA1 and MMSET levels
and 0% for those with high BRCA1 and low MMSET levels
(test for trend: P¼ 0.002).
1.0
Low MMSET (n=25 patients)
High MMSET (n=30 patients)
Median OS, 13.9 months (95% CI = 7.1–20.7 months)
Median OS, 19.1 months (95% CI = 5.2–33.1 months)
P= 0.003
High BRCA1 and low MMSET (n=8 patients)
Median OS, 13.9 months (95% CI = 3.2–24.6 months)
High BRCA1 and high MMSET (n=17 patients)
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Figure 5. Kaplan–Meier estimates of overall survival in advanced gastric cancer patients receiving docetaxel-based second-line chemotherapy
according to (A) MMSET and (B) MMSET/BRCA1 mRNA levels.
Table 2. Median overall survival and HRs for risk of mortality in 74 advanced (stages III–IV) gastric cancer patients receiving only first-line FOLFOX and in
58 patients also receiving second-line docetaxel-based chemotherapy
Only first-line FOLFOX First-line FOLFOX plus second-line docetaxel-based chemotherapy
Variable
Overall survival
Months (95% CI) P-value
Risk of mortality
HR (95% CI) P-value
Overall survival
Months (95% CI) P-value
Risk of mortality
HR (95% CI) P-value
Surgery 0.15 0.16 0.004 0.005
Curative 11.4 (9.2–13.7) 1.00 (Reference) 17.9 (10.3–25.6) 1.00 (Reference)
Palliative 8.8 (6.2–11.5) 1.42 (0.87–2.31) 12.1 (6.3–17.9) 2.47 (1.31–4.66)
BRCA1 0.20 0.20 o0.0001 0.001
p6.2 10.2 (7.3–13.1) 0.72 (0.43–1.20) 9.8 (7.2–12.5) 3.17 (1.61–6.22)
46.2 8.4 (4.4–12.4) 1.00 (Reference) 28.6 (20.2–36.9) 1.00 (Reference)
MMSET 0.04 0.04 0.003 0.004
p6.5 12.3 (7.9–16.8) 0.59 (0.35–0.98) 13.9 (7.1–20.7) 2.52 (1.34–4.70)
46.5 8.8 (5.9–11.7) 1.00 (Reference) 19.1 (5.2–33.1) 1.00 (Reference)
53BP1 0.09 0.09 0.36 0.36
p5.7 10.2 (5.7–14.8) 0.64 (0.38–1.08) 13.9 (5.9–21.9) 1.32 (0.72–2.42)
45.7 9.4 (6.3–12.6) 1.00 (Reference) 17.0 (11.1–22.9) 1.00 (Reference)
MDC1 0.49 0.49 0.07 0.07
p3.3 10.9 (6.4–13.4) 0.83 (0.49–1.40) 12.3 (5.3–19.2) 1.78 (0.95–3.34)
43.3 8.1 (4.3–11.8) 1.00 (Reference) 15.5 (8.5–22.5) 1.00 (Reference)
UBC9 0.01 0.01 0.17 0.17
p1.9 12.4 (10.2–14.5) 0.52 (0.31–0.88) 12.3 (6.6–17.9) 1.52 (0.83–2.77)
41.9 8.8 (5.8–11.8) 1.00 (Reference) 15.2 (8.9–21.5) 1.00 (Reference)
Abbreviations: BRCA1¼breast cancer susceptibility gene 1; CI¼ confidence interval; FOLFOX¼ folinic acid þ fluorouracil þ oxaliplatin; HR¼ hazard ratio; MMSET¼multiple myeloma SET
domain; MDC1¼DNA damage checkpoint protein 1; UBC9¼ubiquitin-conjugating enzyme 9; 53BP1¼p53-binding protein 1.
BRITISH JOURNAL OF CANCER MMSET and survival in gastric cancer
2666 www.bjcancer.com | DOI:10.1038/bjc.2014.231
Multivariable analyses were performed separately in patients
receiving only first-line treatment and in those receiving second-
line treatment. In patients receiving only first-line chemotherapy, a
lower risk of mortality was observed in patients with low MMSET
levels (HR, 0.59; 95% CI, 0.35–0.98; P¼ 0.04) and in patients with
low UBC9 levels (HR, 0.52; 95% CI, 0.31–0.88; P¼ 0.01; Table 2).
In patients receiving second-line chemotherapy, a higher risk of
mortality was observed in patients undergoing palliative surgery
(HR, 2.47; 95% CI, 1.31–4.66; P¼ 0.005), in patients with low
BRCA1 levels (HR, 3.17; 95% CI, 1.61–6.22; P¼ 0.001) and in
patients with low MMSET levels (HR, 2.52; 95% CI, 1.34–4.70;
P¼ 0.004; Table 2).
DISCUSSION
Most gastric cancer patients present with advanced disease and their
prognosis is dismal (Leung et al, 2008). Although there was no
remarkable progress in chemotherapy for advanced gastric cancer in
the 1990s, in the early 2000s new agents and optional treatments
emerged. The ToGA trial (Bang et al, 2010) showed that trastuzumab
confers a survival benefit for patients with HER2-positive gastric
cancer, which comprises 10–20% of patients. Many targeted agents
are currently being investigated and the progress in the treatment of
advanced gastric cancer, including individualised therapy, can be
expected in the near future. We have previously observed that gastric
cancer patients with low ERCC1 mRNA levels could benefit from
FOLFOX chemotherapy (Wei et al, 2008) and that patients with high
BRCA1 levels had longer survival when treated with docetaxel-based
second-line chemotherapy (Wei et al, 2011).
In this study, patients with low levels of MMSET had longer
survival than those with high levels (12.3 vs 8.8 months) when
treated with only platinum-based first-line chemotherapy. Multiple
myeloma SET domain is involved in the t(4 : 14) translocation,
which is present in approximately 15–25% of multiple myelomas
(Asangani et al, 2013). High MMSET protein levels are associated
with high malignant potential in several solid tumours (Glinsky
et al, 2004; Yang et al, 2005; Wurmbach et al, 2007; Xiao et al,
2012; Zhou et al, 2012). Overexpression of MMSET was associated
with increased c-MYC expression, related to the ability of MMSET
to repress the expression of miR-126*, a microRNA targeting
c-MYC (Min et al, 2012), which also has an oncogenic function in
gastric cancer through suppression of SOX2 (Otsubo et al, 2011).
Multiple myeloma SET domain interacts with MDC1 in a DNA
damage-inducible manner and downregulation of MMSET
significantly decreases histone methylation and the subsequent
accumulation of 53BP1 (Pei et al, 2011). A similar effect of
MMSET was also observed in class switch recombination (Pei et al,
2013). Downregulation of MMSET confers hypersensitivity to
DNA damage (Pei et al, 2011).
In contrast to the survival benefit conferred by low MMSET
expression in patients receiving platinum-based treatment,
MMSET expression was higher in docetaxel-sensitive than in
docetaxel-resistant samples in vitro, and moreover, low levels of
MMSET were associated with shorter survival (13.9 vs 19.1
months) in patients receiving docetaxel-based treatment. High
MMSET levels could potentially enhance BRCA1 function, and a
similar differential effect has been reported for BRCA1 expression,
which induces a 10- to 1000-fold increase in resistance to cisplatin
but an 800- to 41000-fold increase in sensitivity to docetaxel
(Quinn et al, 2003, 2007). In our previous study in tumour cells
isolated from malignant effusions of gastric cancer patients, we
observed a similar effect of BRCA1 expression (Wang et al, 2008).
Nevertheless, the most intriguing finding in this study was the
combined effect of MMSET and BRCA1 in patients receiving
second-line docetaxel-based treatment, wherein those with high
levels of both genes attained an unprecedented median survival of
36.6 months compared with 13.9 months in those with high levels
of BRCA1 and low levels of MMSET (P¼ 0.003). The 2-year and
5-year survival rates were also higher in patients with high levels of
both BRCA1 and MMSET (70.6% vs 25% and 33% vs 0%,
respectively). Moreover, in the multivariate analysis, together with
type of surgery, BRCA1 and MMSET levels emerged as significant
markers of survival. This combined effect of MMSET and BRCA1
expression on outcome to docetaxel in advanced gastric cancer
could be explained by the experimental data in myeloma, where
MMSET deregulation affected cell cycle progression and adhesion
regulations, including BRCA1 (Brito et al, 2009). However,
MMSET serves as chromatin modifiers in cancer development. It
functions as a master regulator of transcriptional repression,
activation and oncogenesis (Asangani et al, 2013). The global
impact of MMEST levels in patients beyond DNA damage
response should be further investigated.
In this study, we have also observed striking differences in
survival according to UBC9 expression in patients receiving only
first-line FOLFOX. Patients with low levels of UBC9 attained a
median survival of 12.4 months, in contrast with 8.8 months for
those with high levels (P¼ 0.01). Similar, although nonsignificant,
trends were also observed in patients with low levels of BRCA1,
MDC1 or 53BP1, and a subgroup of patients with low levels of both
MMSET and 53BP1 attained the longest overall survival (19.9
months). In the multivariate analysis, only MMSET and UBC9 levels
significantly influenced survival to first-line FOLFOX. In response to
DNA damage, inhibition of MDC1 results in defective BRCA1 and
53BP1 foci formation after ionising radiation (Goldberg et al, 2003).
Before being transported to DNA damage sites, BRCA1 needs to be
SUMOylated through the activity of UBC9-PIAS1/4 at sites of DNA
damage to increase its ubiquitin ligase activity (Morris et al, 2009).
Ubiquitin-conjugating enzyme 9 is the sole E2-conjugating enzyme
identified for SUMOylation. Ubiquitin-conjugating enzyme 9
depletion impairs 53BP1 accumulation (Galanty et al, 2009).
Dysregulation of UBC9, MMSET, MDC1, 53BP1 and BRCA1
results in aberrant responses to DNA damage, which may have led
to the poorer outcome observed in this subgroup of patients treated
with platinum-based chemotherapy.
To date, there is no gold standard for first-line chemotherapy for
gastric cancer patients, despite a great deal of information on
the heterogeneous biological background of the disease. Moreover, at
the time of failure to first-line chemotherapy, nearly half the patients
could be candidates for further treatment (Ji et al, 2009). This study
provides a tool for selecting patients who will likely benefit from
FOLFOX – based on MMSET and UBC9 – and those who will
benefit from docetaxel – based on BRCA1 (Wei et al, 2011) and
MMSET. Prospective studies are needed to further validate the
potential roles of MMSET and UBC9 on BRCA1 expression-based
personalised therapeutic strategy in gastric cancer patients.
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